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Transforming growth factor a (TGF-a) is a 50-amino acid peptide that is
structurally homologous to vaccinia virus growth factor and epidermal growth
factor (EGF) (1). TGF-a exerts its biologic effects by binding to the EGF receptor
(reviewed in reference 2). It was initially described only in virally transformed
cell lines and in a variety of human tumors, and was demonstrated to cause
transformation in vitro (2-4). However, TGF-a has been shown to inhibit gastric
acid secretion, promote angiogenesis, cause calcium resorption from bone, influ-
ence estrogen metabolism, and promote wound healing in normal tissues (re-
viewed in reference 2). In this report, TGF-a expression in skin from normal
individuals, from patients with psoriasis, and patients with malignantskin diseases
will be demonstrated using an mAb raised against synthetic human TGF-a.
Materials and Methods
Production and Characterization ofmAbs.
￿
mAbs were produced againstsynthetic human
TGF-a (1) using standard methodology (5). Positive hybridoma clones were subcloned
four times by the limiting dilution technique. Epitope mappingof mAb Al . 5 by synthetic
peptides derived from TGF-a (1) was performed using an ELISA with the Vectastain
ABC kit (Vector Laboratories, Inc., Burlingame, CA). EGF was purchased from Collab-
orative Research, Inc. (Bedford, MA).
Immunoperoxidase Staining.
￿
Immunoperoxidase studies of formalin-fixed frozen skin
sections and cytocentrifugedkeratinocyte suspensions wasperformed using the Vectastain
ABC immunoperoxidase staining system (6). Human keratinocytes obtained from either
neonatal foreskin or adult breast skin were cultured in serum-free MCDB 153 medium
(5, 7). For competition experiments, undiluted mAb A1 .5 supernatant was mixed with
purified synthetic human TGF-a (2 ug/ml) immediately before incubation with the skin
sections. Staining was compared with that of the same antibody mixed with an equal
volume of PBSjust before addition .
Results
Characterization of mAb.
￿
From one fusion with splenocytes of 2 mice, 30
positive clones were generated. Three clones, A1 .5, A9.10, and B6.1, exhibited
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FIGURE 1 .
￿
Structure of human TGF-a. The
three synthetic peptide loops used in the anti-
genic specificity studies are indicated by A, B,
and C.
thehighest titers and were chosen forfurther study. All wereofthe IgG1 isotype.
To determine the epitopes recognized by these mAbs, homogeneous synthetic
peptides covering the whole TGF-a molecule were used (Fig. 1). TGF-a is a
tricyclic protein with three disulfide loops. Loops A and B form a fused ring
whereas loop C forms an independent disulfide ring. Loop C represents the
segment with the strongest homology with EGF, with 6 of 10 residues being
conserved (Cysx2GlyTyrxGlyxArgCys; where x represents other amino acids).
In contrast, loop B represents the segment with the least homology with EGF,
with only 4of 17 residues being conserved (Cysx2GlyxCysx,ocys)(1). In a sensitive
ELISA, mAb A1.5 bound to loop B but not loops A or C even at peptide
concentrations of0.1 mg/ml (Fig. 2).
TGF-a is expressed by normal and malignant keratinocytes. Formalin-fixed
frozen skin sections were tested for reactivity with mAb A1.5 using the immu-
noperoxidase technique (Fig. 3). Keratinocytes in eight nodular basal cell carci-
nomas (a and b), one morpheic basal cell carcinoma (d), and one squamous cell
carcinoma (e) demonstrated intense staining with mAb A1.5. Of even greater
interest was the observation that the overlying normal epidermis (c), as well as
the epidermis from five normal skin specimens, were stained by the mAb. The
pattern ofstaining was membranous. Keratinocytes in the epidermalappendages,
which are developmentally derived from basal keratinocytes, were also reactive
with mAb Al.5. mAb A9.10 showed an identical staining pattern, as did mAb
A1.5. mAb B6.1 as well as an isotype control were nonreactive with both normal
and malignant keratinocytes. Keratinocytes in plaques from 18 psoriasis patients
were reactive with mAb A1.5 (Fig. 3f). In general, they were more intensely
f
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FIGURE 3.
￿
Immunoperoxidase reactivity of human skin with the anti-TGF-a mAb, A1.5 .
x 150 . Keratinocytes in nodular (a and b, x 615) and morpheic (d) basal cell carcinomas, and
in a squamous cell carcinoma (e) demonstrated intense staining (black and white arrows). The
overlying epidermis (a, arrowhead ; d), as well as the epidermisfrom normal skin (c, arrow) and
psoriatic plaques (f, arrow) were also stained by the mAb . Themononuclear dermal infiltrates
ofboth psoriasis (fand h, x623) and basal cell carcinoma specimens (a and b) showed reactivity
with mAbA1 .5 . In addition, endothelial cells were reactive (h) . Cultured normal keratinocytes
demonstrated clear membrane reactivity with mAb A1 .5 (g, arrow) .GOTTLIEB ET AL .
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FIGURE 4. TGF-a competi-
tively inhibits binding ofmAb
A1 .5 to skin . x 713 . Synthetic
human TGF-a (2 jug/ml),
when added to mAb Al .5 im-
mediately before the mixture
was incubated with basal cell
carcinoma (b) and normal (d)
skin sections, completely re-
moved theimmunoperoxidase
staining of mAb A1.5 . Sham-
treated mAb A 1 .5 showed re-
activity with the same basal
cell carcinoma (a) and normal
skin (c) sections.
stained than those from normal skin . Cultured normal keratinocytes isolated
from breast skin were trypsinized and then cytocentrifuged onto glass slides .
Clear membrane staining with the anti-TGF-a antibody was observed (Fig . 3g) .
In the mononucleardermal infiltrates of both psoriasisandbasal cellcarcinoma
specimens there was clear reactivity with mAbAl .5 (Fig . 3 h) .We have previously
demonstrated that these infiltrates contained activatedTcells, macrophages, and
Langerhans' cells (6) . In the psoriatic plaques, endothelial cells also appeared to
be stained. The exactidentity ofthe cell(s) reacting with the anti-TGF-a antibody
is still under active investigation.
To confirm that the reactivity of normal and malignant keratinocytes with the
anti-TGF-a antibodies was specific, competition experiments were performed .
Synthetic human TGF-a, at a concentration of 2,ug/ml, was added to mAbAl .5
immediately before the mixture was incubated with basal cell carcinoma and
normal skin sections . TGF-a completely removed the reactivity of mAb A1 .5
with both the basal cell tumor and normal epidermis (Fig . 4) . EGF at similar
concentrations did not compete in binding to mAb A1 .5 .674
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Discussion
TGF-a was demonstrated on the membrane of normal, hyperproliferative,
and malignant keratinocytes. Its presence in normal keratinocytes strongly sug-
gests that it plays an important role in the normal physiological control of
keratinocyte proliferation. Inhibition of TGF-a-induced transformation may be
effected by local cellular and humoral elements as has been described for the
viral myc and ras oncogenes (8).
The presence of TGF-a in keratinocytes and activated platelets (9), along with
its known mitogenic effect, suggests that it may play a significant role in wound
healing. In laboratory animals, TGF-a has been used successfully in treating
experimentally induced wounds (10) . TGF-a and EGF are structurally homolo-
gous to fibronectins, proteoglycans, blood clotting factors IX and X and protein
C (1). These proteins play an important role in the body's response to wounding
and in tissue repair.
Previous studies have focussed on the expression of TGF-a by transformed
cells (2-4). These studies failed to detect TGF-a in normal cultured fibroblasts,
hematopoietic cell lines, and whole liver. However, TGF-a has been detected in
ascites from patients with cirrhosis, breast, activated platelets, and rodent fetuses
(reviewed in reference 2). At the completion of this manuscript, Coffey et al.
(11) reported the production of TGF-a in keratinocytes.
In our studies, it was apparant that TGF-a was present on cells in the dermal
infiltrates of inflammatory, hyperproliferative (psoriasis), and neoplastic skin
diseases. In addition, endothelial cells from psoriatic plaques appeared to contain
TGF-a. Double-labeling immunoperoxidase experiments are in progress to iden-
tify whether macrophages, Langerhans' cells, and/or activated T cells contain
TGF-a. These cells are found in the dermal infiltrates of delayed type hypersen-
sitivity reactions (12, 13) and of inflammatory and hyperproliferative skin diseases
such as psoriasis and lichen planus (6). TGF-a and possibly other factors that
promote keratinocyte proliferation may play a significant role in the generation
of the acanthosis seen in these conditions.
Summary
Transforming growth factor a (TGF-a) is a 50-amino acid peptide, previously
demonstrated only in transformed cell lines and human tumors, which is struc-
turally homologous to epidermal growth factor (EGF). TGF-a expression in
keratinocytes from normal individuals, patients with psoriasis, and patients with
malignant skin diseases was investigated using an mAb raised against synthetic
human TGF-a.
mAb A1 .5 reacted with TGF-a, but not EGF, in a sensitive ELISA. Keratino-
cytes in eight nodular basal cell carcinomas, one morpheic basal cell carcinoma,
and one squamous cell carcinoma demonstrated intense membranous immuno-
peroxidase staining with mAb Al . 5. Of even greater interest was the observation
that the overlying normal epidermis, as well as the epidermis from five normal
skin specimens, were stained by the mAb. Keratinocytes in plaques from 18
psoriasis patients were more intensely stained than those from normal skin.
Cultured normal keratinocytes demonstrated membranous staining with mAb
A1 .5 . Absorption of mAb A1 .5 with synthetic human TGF-a completely re-GOTTLIEB ET AL.
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moved the reactivity of mAb A1 .5 with both basal cell tumors and normal
epidermis .
The demonstration of TGF-a in normal keratinocytes suggests that it plays a
role in normal keratinocyte growth, wound healing, and in the pathogenesis of
acanthosis.
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